Growth hormone does not reliably raise live birth rates for the average IVF patient, and routine use is not supported by high-certainty evidence. Certain subgroups, including some poor responders and women of advanced maternal age, show possible benefit in smaller studies, though results are inconsistent. This summary draws on a Cochrane-adjacent systematic review, recent meta-analyses, and a large randomized controlled trial, and growth hormone remains an off-label addition that calls for clinician oversight and informed consent.

TL;DR:

Growth hormone shows potential benefits for certain poor responders and women with thin endometrium, but evidence remains inconsistent and low to moderate in quality.

Large trials and meta-analyses indicate no significant improvement in live birth or pregnancy rates for unselected IVF populations when GH is added empirically.

The effectiveness of GH may depend on individual biomarkers like ovarian reserve, age, and endometrial thickness, but no definitive predictors are established.

Variations in dosing, timing, and protocols across studies complicate identifying an optimal regimen and hinder broad recommendations.

GH use requires careful clinician oversight, informed consent, and monitoring due to safety concerns and off-label status, with costs and access being variable.

Lifeivfcenter

Explore A More Personalized IVF Approach

Life IVF Center customizes treatment protocols around your biological profile, medical history, and reproductive goals.

Visit Life IVF Center

What the clinical evidence says about growth hormone and IVF outcomes
Who may benefit: subgroup evidence and clinical profiles
How growth hormone is administered in studies: doses, timing, and protocol differences
Safety, contraindications, and monitoring for GH use in IVF
Practical considerations: off-label use, brands, cost, and access
How clinicians decide: questions to ask and shared decision-making checklist
How Life IVF Center evaluates growth hormone within Precision IVF®
The honest take on growth hormone in IVF
Why Life IVF Center fits this conversation
Sources
FAQ

What the clinical evidence says about growth hormone and IVF outcomes

The research picture on growth hormone in IVF is best described as promising in pieces but unconvincing as a whole. Reviewers consistently note two things: some outcome measures move in a favorable direction for certain patients, and the overall certainty of that evidence stays low to moderate because trials vary so much in design.

A broad overview of meta-analyses covering growth hormone supplementation found that GH may improve clinical pregnancy rates and oocyte yield in selected poor responder subgroups, but there is no consistent evidence of increased live birth rates across general IVF populations. That distinction matters: a treatment can nudge an intermediate outcome, like egg count, without translating into more babies born, which is the outcome patients actually care about.

A separate meta-analysis looking specifically at endometrial function found that GH was associated with increased endometrial thickness and improved clinical pregnancy in some subgroups, including poor responders and patients with thin endometrium. The same review rated its evidence quality as ranging from low to moderate, a caveat that shows up again and again in this literature.

Then there is the largest trial to date, which complicates any case for routine use. A phase III randomized controlled trial enrolling 288 patients in a general IVF population found no improvement in stimulation outcomes or reproductive endpoints when GH was added empirically to standard antagonist cycles. Retrieved oocytes, implantation, clinical pregnancy, and live birth rates all came back statistically similar between the GH and control groups.

A 2025 phase III RCT (n=288) found no significant difference in live birth, clinical pregnancy, or oocyte yield when GH was added empirically to standard IVF cycles, reinforcing that unselected use offers little measurable advantage.

Why do subgroup studies and this large trial point in different directions? A few recurring issues explain most of the gap:

Trials define “poor responder” inconsistently, sometimes by egg count, sometimes by age, sometimes by prior cycle failure, which makes pooling results across studies unreliable.
Sample sizes in many subgroup trials are small, often under 100 participants per arm, which inflates the chance that an apparent benefit is a statistical fluke.
Dosing, timing, and stimulation protocols differ from one study to the next, so a positive signal in one trial may reflect its specific regimen rather than growth hormone itself.
Endpoints vary: some trials measure oocyte number, others measure endometrial thickness, and only a minority report live birth, the outcome with the most clinical weight.

Heterogeneity like this is the main reason professional reviews stop short of recommending GH broadly. The honest read of the literature is that growth hormone may help a narrow slice of patients under specific circumstances, but it is not a general-purpose upgrade to an IVF cycle.

Who may benefit: subgroup evidence and clinical profiles

Because the overall evidence is mixed, the more useful question for most patients is not “does GH work” but “does GH work for someone like me.” Three patient profiles come up repeatedly in the literature.

Poor responders, typically defined as patients who produce few eggs despite standard stimulation, are the group most often studied. Diminished ovarian reserve overlaps heavily with this category. Findings here are genuinely mixed: some meta-analyses report modest gains in oocyte number and clinical pregnancy, while the largest RCT to date found no benefit at all in a broader IVF population that included lower responders. The honest summary is that a subset of poor responders might see a measurable difference, but no biomarker reliably identifies which ones in advance.

Women of advanced maternal age represent the second group of interest. Pooled analyses in some studies reported higher clinical pregnancy and live birth odds with GH cotreatment in this population, a more encouraging signal than the general-population data. Even so, the same review cautions that the result needs confirmation because of small sample sizes and heterogeneity across the pooled trials. It is a lead worth discussing with a fertility team, not a settled conclusion.

Patients with thin endometrium form the third profile. The endometrial function meta-analysis mentioned earlier found this group showed increased lining thickness and improved clinical pregnancy with GH, though again at low to moderate evidence quality. Thin endometrium is one of the more biologically plausible targets for GH, since growth hormone is thought to support endometrial receptivity, but plausibility is not the same as proof.

A few biomarkers come up as possible signals rather than confirmed predictors:

Low AMH, a marker of ovarian reserve, is often used to identify poor responders who might be considered for GH, though it does not reliably predict who will respond.
Low IGF-1 levels are sometimes flagged as a marker of patients who could be better candidates, supporting a more individualized approach rather than blanket use.
Endometrial thickness on ultrasound helps identify patients in the thin endometrium subgroup, but a thin lining alone does not guarantee a GH response.

Pro Tip: Ask your fertility team whether your specific profile (poor responder, advanced maternal age, or thin endometrium) matches a subgroup where GH has shown a signal in the literature, rather than assuming general benefit.

How growth hormone is administered in studies: doses, timing, and protocol differences

One reason pooled GH data is hard to interpret is that trials rarely use the same regimen. Dosing, start timing, and total duration all vary, and those differences likely affect outcomes independently of whether GH works at all.

Daily dose. Trial dosing for somatropin products in IVF protocols commonly falls in a range of roughly 3 to 10 IU per day, though exact amounts and units differ by product and study, which complicates direct comparison between trials.
Start timing. Some protocols begin GH in the luteal phase of the cycle preceding stimulation, aiming to prime follicles before gonadotropins start. Others begin dosing on day one of ovarian stimulation and continue through to the trigger shot.
Duration. Total length of GH exposure ranges from a few days around stimulation to several weeks when luteal-phase priming is used, and longer exposure in some trials correlates with different outcome patterns than short courses.
Protocol pairing. GH has been studied alongside both GnRH agonist and antagonist stimulation protocols, and some subgroup analyses suggest the pairing may influence the size of any observed effect, though this has not been consistently confirmed.

A 2023 systematic review quantified one consistent downstream effect of GH cotreatment: it reported a mean difference of 460.97 IU less total gonadotropin needed during stimulation, along with a modest reduction in stimulation length of 0.26 days on average. That finding is one of the more reproducible signals in this literature, even where pregnancy and live birth data stay uncertain, and it suggests GH may make the ovaries more responsive to stimulation drugs without necessarily changing how many cycles end in a baby.

Dose and timing differences may also help explain the split between endometrial and oocyte outcomes. Some pooled analyses suggest that lower daily dosing starting earlier in the cycle shows a different signal for endometrial thickness than for egg or embryo quality, according to a meta-analysis on dose and timing effects. No single regimen has been established as optimal, and that uncertainty is a core reason major reviews stop short of a standard recommendation.

Safety, contraindications, and monitoring for GH use in IVF

Growth hormone is a potent systemic hormone, not a benign fertility supplement, and that distinction should shape how it gets discussed and consented to. FDA prescribing information for marketed somatropin products lists several contraindications that matter regardless of why GH is being used.

FDA labeling for somatropin products lists active malignancy as a contraindication, among other serious warnings relevant to any off-label use, according to Genotropin’s prescribing information. That single data point should be part of any informed consent conversation before GH is added to an IVF cycle.

Key safety considerations drawn from somatropin labeling include:

Active malignancy is a contraindication, since growth hormone can theoretically support tumor growth.
Acute critical illness, including complications following major surgery or trauma, is another listed contraindication.
Severe diabetic retinopathy is flagged as a concern, since GH can affect glucose metabolism and vascular changes in the eye.
Glucose intolerance and insulin resistance are known risks, making blood sugar monitoring relevant during treatment.

A revised label for Omnitrope, updated as recently as 2025, reiterates similar safety and dosing considerations for somatropin products generally, which reinforces that these warnings are not specific to one brand but apply across the drug class.

Monitoring during GH use typically covers glucose levels, thyroid function, and IGF-1, since IGF-1 is the hormone GH stimulates the liver to produce and serves as a rough marker of dosing adequacy and systemic exposure. Patients with preexisting diabetes, thyroid disease, or other metabolic risk factors may benefit from coordinated input from an endocrinologist alongside the fertility team. Because GH affects systemic metabolism beyond the reproductive system, clear informed consent and ongoing surveillance are not optional extras, they are the baseline standard for responsible off-label use.

Practical considerations: off-label use, brands, cost, and access

Growth hormone is not approved by regulators specifically for fertility treatment, which means any use in IVF is off-label. That status does not make it illegal or inappropriate, but it does shift the burden onto the clinical team to document a clear rationale, obtain explicit informed consent, and set a monitoring plan before starting treatment. Patients considering GH should expect that conversation, not a casual add-on to their protocol.

Several somatropin brands appear across the published trials and reviews, including Genotropin, Omnitrope, and Saizen, the product name used in one of the large randomized trials. Different studies use different products, and since formulations and delivery devices vary slightly between brands, results from a trial using one product do not automatically generalize to another.

Cost is driven by a mix of factors:

Total daily dose and duration of treatment, since longer courses and higher doses require more medication.
Brand selection, as pricing can differ between somatropin products even at equivalent doses.
Whether the medication is sourced through standard pharmacy channels or a compounding pharmacy, which can affect both price and regulatory oversight.
Insurance coverage, which is inconsistent for off-label fertility uses of GH, leaving many patients paying out of pocket.

Because GH is not a standard covered component of most IVF cycles, patients should ask for a clear cost estimate before starting, separate from the core cycle fees.

How clinicians decide: questions to ask and shared decision-making checklist

Deciding whether to add growth hormone to an IVF cycle works best as a structured conversation rather than a single yes-or-no moment. A short checklist can help patients walk into that conversation prepared.

What specific outcome is GH expected to improve in my case, and what is the evidence behind that expectation for someone with my profile?
What dose, timing, and duration would be used, and how does that compare with the regimens studied in published trials?
What is the monitoring plan, including which labs will be checked and how often?
Are there any contraindications in my medical history, such as a history of cancer, diabetic eye disease, or acute illness, that would rule out GH?
What are the alternatives to GH for my specific concern, and what do they cost by comparison?

An individualized workup, the kind built into Precision IVF®, changes this calculus by starting from the patient’s own biomarkers and history rather than a one-size-fits-all protocol. That means GH gets considered only when a patient’s profile plausibly matches the subgroups where trial signals exist, not applied by default.

Pro Tip: Be cautious of any clinic that promises guaranteed results from growth hormone, skips a documented monitoring plan, or does not screen for contraindications before prescribing it.

How Life IVF Center evaluates growth hormone within Precision IVF®

The Precision IVF® approach begins with a full review of a patient’s biology before any adjunct therapy, including growth hormone, enters the conversation. That means a history review, relevant biomarker testing, and a look at prior cycle data where available, all before a protocol gets drafted.

When growth hormone is considered as a possible addition, it is weighed against a patient’s specific profile: ovarian reserve markers, age, endometrial findings, and any contraindications flagged in the medical history. GH is considered only after that review, and only with a documented monitoring plan covering the relevant labs, such as glucose and IGF-1, discussed earlier in this guide. This mirrors the shared decision-making checklist above: expected benefit, specific protocol, contraindication screening, and alternatives are all part of the same conversation before any adjunct therapy is added to a cycle.

For readers who want this kind of individualized evaluation applied to their own case, including whether growth hormone or another adjunct makes sense for their biology, Life IVF Center’s treatment packages outline how consultation and cycle planning fit together, and a consultation is the starting point for that discussion.

The honest take on growth hormone in IVF

The conventional pitch around growth hormone in IVF tends to lean on biological plausibility: GH affects follicles and endometrium, so it sounds like it should help. The evidence does not back that leap. The largest trial to date found nothing in a general population, and even the more encouraging subgroup data comes with explicit caveats about small samples and inconsistent definitions.

What gets underweighted in most patient-facing discussions is how much the “poor responder” and “advanced maternal age” labels vary from one study to the next. A patient told she fits a subgroup that benefited in one trial may not fit the definition used in a different, less favorable trial. The priority, before anything else, should be matching your own biomarkers and history against the specific subgroup criteria in the studies that showed a signal, not against the subgroup label in general. Growth hormone may be worth a conversation for some patients. It is not a default upgrade, and no current evidence supports treating it as one.

— Ben

Why Life IVF Center fits this conversation

Patients weighing an adjunct therapy like growth hormone need a clinic willing to have the detailed, evidence-based conversation this guide has walked through, not a blanket recommendation. Life IVF Center’s Precision IVF® approach is built around reviewing each patient’s biology, history, and prior cycle data before any protocol decision gets made, which is exactly the kind of groundwork that subgroup-specific therapies like GH require.

If you are wondering whether your own profile matches the patients who showed a benefit in the research summarized here, that question deserves a direct answer from a team that has reviewed your full history. You can start that conversation by looking at Life IVF Center’s treatment packages or booking a consultation to discuss your specific case.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

Is HGH effective in IVF?

Growth hormone (HGH) is not consistently effective across the general IVF population: a large phase III randomized trial found no improvement in stimulation or reproductive outcomes when added empirically, and GH dosing protocols are further detailed in this tiered protocol and safety guide. Some subgroups, including certain poor responders and women of advanced maternal age, show possible benefit in smaller studies, but the evidence quality is low to moderate.

Why are IVF babies mostly boys?

Overall sex ratios among IVF births are not clearly established as skewed toward boys in the sources reviewed for this guide, and this topic falls outside the growth hormone evidence covered here. Patients with questions about embryo sex ratios should raise them directly with their fertility team, since the answer depends on specific lab and protocol factors not addressed in the GH literature above.

What did changes to IVF policy do for access to treatment?

Policy discussions around IVF access have occurred at various points, but no specific legislative or executive action is covered by the sources used in this article. Patients with questions about coverage or policy changes affecting their treatment should check current guidance from their insurance provider or a qualified legal resource.

How much does Omnitrope cost in IVF?

Omnitrope’s prescribing information does not list a patient price, since cost depends on dose, duration, and pharmacy channel rather than a fixed figure. Because GH is used off-label in IVF, coverage is inconsistent, and many patients pay out of pocket, making a direct cost conversation with the prescribing clinic and pharmacy the most reliable way to get an accurate figure.

What dose of growth hormone is used in IVF protocols?

Trial dosing for somatropin in IVF protocols commonly falls in a range of roughly 3 to 10 IU per day, though exact amounts vary by product and study. Timing also differs: some protocols start in the luteal phase before stimulation, while others begin on day one of stimulation and continue through the trigger shot.

This article is for general educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Fertility care is highly individual; please consult a qualified healthcare professional about your specific circumstances.

Uncategorized

Growth Hormone in IVF: 288 Patient RCT and Who Might Still Benefit

Table of Contents